DrugPipeline.net has announced the addition of “Peanut Allergy - Pipeline Insight, 2018” research report to their website www.DrugPipeline.net

Bangalore, India -- (SBWire) -- 05/16/2018 --Peanut Allergy - Pipeline Insight, 2018 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Peanut Allergy development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Peanut Allergy
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Peanut Allergy
The report assesses the active Peanut Allergy pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by Publisher's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
- The report provides a snapshot of the pipeline development for the Peanut Allergy
- The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Peanut Allergy
- The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Peanut Allergy
- The report also covers the dormant and discontinued pipeline projects related to the Peanut Allergy

Reasons to Buy
- Establish comprehensive understanding of the pipeline activity across this Peanut Allergy to formulate effective R&D strategies
- Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
- Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Peanut Allergy therapeutics
- Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Spanning over 50 pages "Peanut Allergy - Pipeline Insight, 2018" report covers Report Introduction, Peanut Allergy Overview, Pipeline Therapeutics, Comparative Analysis, Products in Clinical Stage, Products in Pre-Clinical and Discovery Stage, Therapeutic Assessment, Inactive Products, Appendix. This report Covered Companies - Adverum Biotechnologies Inc, Aimmune Therapeutics Inc, Alfacyte Ltd, Allergy Therapeutics Plc, AnaptysBio Inc, ASIT Biotech SA, Astellas Pharma Inc, BioLingus AG, DBV Technologies SA, HAL Allergy BV, & list continues.

For more information Visit at: https://www.drugpipeline.net/delveinsight/peanut-allergy-pipeline-insight-2018

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Surepost - API Insight,2018 - Visit at - https://www.drugpipeline.net/delveinsight/surepost-api-insight2018

Cholecystokinin Receptor (CCK) Antagonist -Pipeline Insight, 2018 - Visit at - https://www.drugpipeline.net/delveinsight/cholecystokinin-receptor-cck-antagonist-pipeline-insight-2018

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.